7,580.79

+39.39

+0.52%

51,787.66

-196.32

-0.38%

25,424.98

+260.62

+1.04%

2,822.83

+16.95

+0.60%

4.9580

+0.0640

+1.31%

20.96

-0.19

-0.90%

3,938.40

-31.20

-0.79%

77,603.37

+575.00

+0.75%

Crude Oil Dec 26

95.82

-0.64

-0.66%

US Private Equity

10,836.30

-14.33

-0.13%

NasdaqCM - Nasdaq Real Time Price USD

Incannex Healthcare Inc. (IXHL)

2.5000 +0.1200 (+5.04%)

As of 12:22:41 PM EST. Market Open.

Loading Chart for IXHL

Chart Range Bar

Interval:

In partnership with ChartIQ

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) FY26

Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) FY26

Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X

Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X

Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026

Incannex Receives Additional A$5.1 Million R&D Tax Incentive Refund, Completing More Than A$11.2 Million in Non-Dilutive Capital Received in 2026

Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea

Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea

Incannex (IXHL) Secures U.S. Patent Grant in Obstructive Sleep Apnea for IHL-42X

Incannex (IXHL) Secures U.S. Patent Grant in Obstructive Sleep Apnea for IHL-42X

Incannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position

Incannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position

Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea

Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea

Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility

Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility

Incannex Announces Initiation of Research Coverage by Alliance Global Partners

Incannex Announces Initiation of Research Coverage by Alliance Global Partners

Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea

Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea

Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development

Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development

Mobilize your Website

View Site in Mobile | Classic

Share by: